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Main points 22 
1.Prosaptide TX14(A), a fragment of Saposin C, acts via GPR37L1/GPR37 on astrocytes and23 
protects them from the oxidative stress. 24 
2. In HEK293 cells GPR37L1 and GPR37 are dysfunctional.25 
3. GPR37L1/GPR37 signaling in astrocytes enables neuroprotection.26 
27 
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ABSTRACT 44 
Discovery of neuroprotective pathways is one of the major priorities for neuroscience. 45 
Astrocytes are the natural neuroprotectors and it is likely that brain resilience can be 46 
enhanced by mobilising their protective potential. Among G-protein coupled receptors 47 
expressed by astrocytes, two highly related receptors, GPR37L1 and GPR37, are of particular 48 
interest. Previous studies suggested that these receptors are activated by a peptide Saposin 49 
C and its neuroactive fragments (such as prosaptide TX14), which were demonstrated to be 50 
neuroprotective in various animal models by several groups. However, pairing of Saposin C 51 
or prosaptides with GPR37L1/GPR37 has been challenged and presently GPR37L1/GPR37 52 
have regained their orphan status. Here we demonstrate that in their natural habitat, 53 
astrocytes, these receptors mediate a range of effects of TX14, including protection from 54 
oxidative stress. The Saposin C/GPR37L1/GPR37 pathway is also involved in the 55 
neuroprotective effect of astrocytes on neurons subjected to oxidative stress. The action of 56 
TX14 is at least partially mediated by Gi-proteins and the cAMP-PKA axis. On the other hand, 57 
when recombinant GPR37L1 or GPR37 are expressed in HEK293 cells, they are not 58 
functional and do not respond to TX14, which explains unsuccessful attempts to confirm the 59 
ligand-receptor pairing. Therefore this study identifies GPR37L1/GPR37 as the receptors for 60 
TX14, and, by extension of Saposin C, and paves the way for the development of 61 
neuroprotective therapeutics acting via these receptors.  62 
63 
64 
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Neuroprotection, astroprotection, orphan receptors, GPR37L1, GPR37, Saposin C, 66 
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Introduction 70 
Any new target for effective neuroprotective therapy must be actively explored as it may 71 
have major medical and societal impacts. Orphan G-protein coupled receptors (GPCRs) are 72 
particularly attractive because they are the most plausible targets for modern small 73 
molecule drugs, but this approach critically depends on identification of their endogenous 74 
agonists. The search for druggable targets in the brain conventionally focused on neurons, 75 
but astrocytes as natural neuroprotectors represent particularly attractive drug targets. 76 
Their neuroprotective mechanisms are numerous and include uptake of glutamate to 77 
prevent neurotoxicity, regulation of extracellular ions and pH, provision of anti-oxidative 78 
molecules (e.g. glutathione) and trophic factors, control micro-circulation, etc. (Liu et al., 79 
2017). 80 
In 1994 peptide prosaposin (PSAP) and its fragment Saposin C (Sap C) were identified as 81 
neurotrophic factors using the neuroblastoma NS20 line and specific binding of radio-82 
labelled Sap C with a Kd of 19 pM was demonstrated (O'Brien et al., 1994). Soon it was 83 
shown that chronic icv infusion of recombinant PSAP almost completely prevented 84 
ischemia-induced learning deficits and neuronal loss in gerbils (Sano et al., 1994) and the 85 
existence of a GPCR for the neuroprotective part of Sap C was thus postulated (Hiraiwa et 86 
al., 1997). The experimental usefulness of SPAP and Sap C is limited by their length but 87 
luckily, the neuroactive part is rather short and can be mimicked by peptides known as 88 
prosaptides, of which the most studied is prosaptide TX14(A). The sequence of TX14(A) is 89 
highly evolutionarily conserved (Fig. S1). Although neuroprotective effects of PSAP 90 
fragments were demonstrated in several models in vitro and in vivo (Campana et al., 91 
1998;Hozumi et al., 1999;Otero et al., 1999;Gao et al., 2016), the underlying mechanism 92 
remained unclear until 2013, when two closely related orphan receptors GPR37L1 and 93 
GPR37 (Leng et al., 1999) were proposed to mediate the actions of PSAP and its mimetics 94 
(Meyer et al., 2013). 95 
GPR37L1 is highly expressed by astrocytes, which also express low levels of GPR37 (Fig S2, 96 
S3) (Zhang et al., 2014;Marazziti et al., 2007;Jolly et al., 2017;Smith, 2015)). GPR37 is highly 97 
expressed in dopaminergic neurons and early work focused on the idea of GPR37 being 98 
involved in Parkinson’s disease (Imai et al., 2001;Cantuti-Castelvetri et al., 2007;Marazziti et 99 
al., 2007). The importance of GPR37L1 for brain function has been recently demonstrated in 100 
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humans. A point mutation in GPR37L1 leads to a severe neurological phenotype with 101 
includes intractable epilepsy, lethal in some of the affected individuals (Giddens et al., 102 
2017). GPR37L1- and especially double GPR37L1/GPR37-knockout mice were highly 103 
susceptible to seizures (Giddens et al., 2017). Moreover, deletion of GPR37L1 drastically 104 
increased the neuronal loss after an ischemic stroke (Jolly et al., 2017). These and other 105 
findings underscore the importance of GPR37L1 for brain health. 106 
However, the pairing of GPR37L1/GPR37 with PSAP and TX14(A) (Meyer et al., 2013) was 107 
later challenged. It was reported that these receptors are highly constitutively active and 108 
couple via Gs proteins, rather than the Gi pathway as originally reported (Meyer et al., 109 
2013). Moreover, on the background of their high constitutive activity, TX14(A) was 110 
ineffective (Coleman et al., 2016;Giddens et al., 2017;Ngo et al., 2017). Regulation of this 111 
constitutive activity was suggested to occur via cleavage of the extracellular part of GPR37L1 112 
(Mattila et al., 2016;Coleman et al., 2016). These reports reinforced the skepticism based on 113 
the failure of TX14(A) to activate GPR37L1/GPR37 using the DiscoverX orphan receptor 114 
screening panel (Smith, 2015;Southern et al., 2013). Importantly, all studies reporting high 115 
constitutive activity of GPR37L1 and GPR37 and lack of TX14(A) agonism relied on 116 
expression of recombinant GPR37L1 in either HEK293 or CHO cells (Ngo et al., 2017;Giddens 117 
et al., 2017;Southern et al., 2013) or yeast (Coleman et al., 2016).  118 
Thus, the nature of the endogenous agonist of GPR37L1 and GPR37 is currently elusive. 119 
High constitutive activity of GPR37L1/GPR37 should lead to persistent production of copious 120 
amounts of cAMP. However, this has never been noticed in astrocytes where GPR37L1 is 121 
particularly abundant (Fig S2, S3). To the contrary, astrocytes vigorously respond to stimuli 122 
which increase cAMP production (such as agonists of Gs-coupled receptors or low 123 
concentrations of forskolin), indicating that their resting levels of cAMP are not anywhere 124 
near saturation, see for example (Goldman & Chiu, 1984;Tardy et al., 1981;Clark & Perkins, 125 
1971) and numerous other studies. 126 
We hypothesized that coupling of GPR37L1/GPR37 in transiently transfected cell lines does 127 
not reveal their true physiological signaling and re-evaluated them in their natural habitat, 128 
the astrocytes. Our findings demonstrate that PSAP is, indeed, the natural ligand of 129 
Page 6 of 51GLIA
GPR37L1/GPR37 and pave the way for development of neuroprotective drugs based on this 130 
signaling system. 131 
132 
Materials and Methods 133 
134 
Primary cultures of astrocytes and cortical neurons 135 
Experiments were performed in accordance with the UK Animals (Scientific Procedures) Act, 136 
1986 and were approved by the University of Bristol ethics committee. 137 
Astrocytes: Primary cultures of astrocytes were prepared from the cerebral cortices, 138 
cerebellum and brainstem from Wistar rat pups (P2) following protocols described 139 
previously (1-3). Briefly, the brains of Wistar P2 pups were dissected out, crudely cross-140 
chopped and bathed in a solution containing HBSS, DNase I (0.04 mg/ml), trypsin from 141 
bovine pancreas (0.25 mg/ml) and BSA (3 mg/ml). The preparation was agitated at 37 °C for 142 
15 mins. Trypsinization of the brain tissue was terminated by the addition of equal volumes 143 
of culture media comprised of DMEM, 10% heat-inactivated FBS, 100 U/ml penicillin and 0.1 144 
mg/ml streptomycin and then centrifuged at 2000 rpm, at room temperature (RT) for 10 145 
mins. The supernatant was aspirated, and the remaining pellet was resuspended in 15 ml 146 
HBSS containing BSA (3 mg/ml) and DNase I (0.04 mg/ml) and triturated gently. After the 147 
cell debris had settled, the cell suspension was filtered through a 40 μm cell strainer (BD 148 
Falcon) and cells were collected after centrifugation. Cells were seeded in a T75 flask 149 
containing culture media (see above) and maintained at 37 °C with 5% CO2. Once the 150 
cultures reached confluence and one week later, the flasks were mildly shaken overnight to 151 
remove microglia and oligodendrocytes. When astrocytes were seeded for experiments, 152 
media was changed to DMEM supplemented with 5% FBS instead of 10% FBS. This is to 153 
reduce the content of PSAP in the culture media hence make PSAP depletion easier to 154 
achieve. Please note there was no difference in cell growth in the media containing either 155 
5% or 10% FBS.  156 
Neurons: Cerebral cortices were dissected out from a litter (8-12) of Wistar rat embryos on 157 
gestation day 18 (E18) and collected in dissection saline (HBSS, 25.6 mM glucose, 10 mM 158 
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MgCl2, 1 mM Hepes, 1 mM kynurenic acid, 0.005% phenol red, 100 U/ml penicillin, 0.1 159 
mg/ml streptomycin). Meninges were removed, and tissues were chopped into pieces <1 160 
mm3 and dissociated in 0.25% Trypsin in dissection saline in the presence of 3 mg/ml BSA at 161 
37°C for 15 mins. An equal volume of plating media (Neurobasal A with 5% horse serum, 2% 162 
B27, 400 nM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin) was added to 163 
terminate the dissociation. Cells were pelleted at 2000 rpm for 5 mins at room temperature, 164 
resuspended in plating media, and triturated gently. The cell suspension was diluted 165 
appropriately and passed through a 40 µM cell strainer. 1x10
5
 cells per well were plated on 166 
poly-D-lysine-coated glass cover slips in 24-well plates. Two hours later, the plating media 167 
was replaced with feeding media (Neurobasal A with 2% B27, 800 nM L-glutamine, 20 U/ml 168 
penicillin, 20 µg/ml streptomycin). On day 5, half of the media was replaced with feeding 169 
media in which glutamine was replaced with 4 µM Glutamax. The antimitotic cytosine β-D-170 
arabinofuranoside (10 µM) was added to control glial contamination. Neurons were used for 171 
experiments 10 days later. 172 
Neuron/astrocyte co-cultures: Neurons were prepared (see above) and plated at 1x105 cells 173 
per well on poly-D-lysine-coated glass coverslips in 24 well plates. Astrocyte inserts were 174 
prepared by plating astrocytes on poly-D-lysine-coated cell culture inserts with 1 µm 175 
diameter pores (Greiner Bio-One) in the same serum-free media as used for neurons. 176 
Astrocyte inserts were introduced into neuronal cultures as required. The separation 177 
between both cell types allowed secreted molecules to freely diffuse while preventing direct 178 
astrocyte-to-neuron contact. 179 
180 
Real Time PCR on primary cultured and acutely isolated astrocytes 181 
In order to verify that the expression of GPR37L1 and GPR37 in our cultured astrocytes is 182 
not an result of in vitro conditions, we performed acute vibro-isolation of cortical astrocytes 183 
frim P12 rats using a method recently described by Lalo and Pankratov(Lalo & Pankratov, 184 
2017). ~50 single astrocytes were manually collected from the bottom of a small Petri dish 185 
into a sterile test tube. Power SYBR Green Cells-to-Ct Kit (Ambion) was used to reverse 186 
transcription directly from cultured cell lysates, without isolating RNA. The resulting cDNA 187 
samples were then analysed using QuantiTect SYBR green PCR kit (Qiagen) on DNA Engine 188 
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OPTICON 2 continuous fluorescence detector, following the manufacturer's protocol. β-189 
actin was used as a reference house-keeping gene. All primers were designed to span at 190 
least one intron and to produce products of ~100 bp and pre-validated for their efficiency. 191 
Products of PCR reaction were resolved on agarose gel to confirm their sizes (Fig. S3). 192 
Sequences of the primers are shown below. 193 
β-Actin forward: CTAAGGCCAACCGTGAAAAG 194 
reverse: GGCATACAGGGACAACACAG 195 
GPR37L1 forward: ATGTTTCTTGCCGAGCAGTG 196 
GPRF37L1 reverse: CCACATGGAATCGGTCTATG 197 
GPR37 forward: TCCATGAGTTGACCAAGAAG 198 
GPR37 reverse: CTATGCACAGTGCACATAAG 199 
GFAP forward: GAGAGGAAGGTTGAGTCGCT 200 
GFAP reverse: CACGTGGACCTGCTGCTG 201 
202 
Western blotting 203 
For verification of GPR37L1/37 knock down viral vectors AVV-CMV-EmGFP-miR155/GPR37L1 204 
and AVV-CMV-EmGFP-miR155/GPR37, transduced astrocytes were harvested and placed on 205 
ice and washed with ice-cold phosphate-buffered saline (PBS). The membrane proteins were 206 
then extracted using the Mem-PER eukaryotic membrane protein extraction reagent kit 207 
(PIERCE) and purified with SDS-PAGE sample preparation kit (PIERCE). After quantification 208 
with BCA protein assay kit (PIERCE), 20 μg of membrane protein per lane were fractionated 209 
on a 4–12% Bis-Tris gel (NuPage 4–12% Bis-Tris Gel, Life Technologies), and transferred to a 210 
polyvinylidene difluoride (PVDF) membrane (Millipore). After blocking with 5% non-fat dry 211 
milk (NFDM) in Tris-buffered saline with 0.1% tween-20 (TBST) buffer for 45 mins at RT, the 212 
PVDF membrane was cut into two parts at 100KD-size level. The part of the membrane 213 
containing small sized proteins was incubated with primary antibody to GPR37L1 (1:1000 214 
dilution) or GPR37 (1:1000 dilution) in 3% NFDM-TBST at 4℃ overnight, and the other part 215 
of membrane was incubated with primary antibody to pan-cadherin (120Kda) (1:2000 216 
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dilution) as a membrane protein loading control, in 3% NFDM-TBST at 4℃ overnight. 217 
Following incubation with horseradish peroxidase conjugated secondary antibody (DAKO, 218 
1:2000 dilution) for 90mins at RT, the immunoreactivities were detected with Immun-Star 219 
Western C chemiluminescent kit (Bio-Rad). For the PSAP depletion assay and the proof of 220 
the existence of PSAP in serum-supplemented culture media, we used the same protocol as 221 
described above except that 5 μl of media or elution from protein A magnetic beads was 222 
applied as the sample volume. A polyclonal rabbit anti-PSAP antibody was employed. For 223 
Western blotting of PSAP in neuron-astrocyte co-culture media, we changed to the 224 
Amersham ECL Plex western blotting system using a low-fluorescent PVDF membrane (GE 225 
Healthcare) and Alexa Fluor 488 secondary antibody-conjugated goat anti-rabbit. Protein 226 
transfer and membrane blocking was the same as in the above protocol. Membranes were 227 
incubated with anti-PSAP (1:500 dilution) overnight at 4 °C. Secondary antibody Alexa Fluor 228 
488 was incubated for one hour in the dark at room temperature. Before imaging, the 229 
membrane was thoroughly washed. Signal was detected by scanning the membrane on a 230 
fluorescent laser scanner (Typhoon, GE Healthcare).  231 
232 
Generation of knock-down adenoviral vectors (AVV) 233 
AVV for the knock-down experiments were based on a modified Pol II miR RNAi Expression 234 
Vector system (Invitrogen) and our previous work (Liu et al., 2010). Three AVV were 235 
constructed, namely, AVV-CMV-EmGFP-miR155/GPR37L1, AVV-CMV-EmGFP-miR155/GPR37 236 
and AVV-CMV-EmGFP-miR155/negative. The first two were used for knocking down 237 
GPR37L1 and GPR37 in astrocytes, respectively. The third one is a negative control, 238 
harboring a miRNA sequence that can form a hairpin structure that is processed into mature 239 
miRNA but is predicted not to target any known vertebrate gene. All three vectors were 240 
made based on BLOCK-iT™ Pol II miR RNAi Expression Vector Kit with EmGFP (Invitrogen). 241 
This system supports chaining of miRNAs, thus ensuring co-cistronic expression of multiple 242 
miRNAs for knock down of a single target. Three sets of two complementary single-stranded 243 
DNA microRNA sequences (targeting different regions of the same gene) for GPR37L1 and 244 
GPR37 were designed by the BLOCK-iT™ RNAi Designer (Invitrogen). The complementary 245 
single-stranded oligos were then annealed and cloned into the linearized pcDNA™6.2-246 
GW/EmGFP-miR vector. The pre-miRNA expression cassettes were transferred into an 247 
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adeno shuttle plasmid pXcX-Sw-linker (Duale et al., 2005), resulting in construction of pXcX-248 
CMV-EmGFP-miR155/GPR37L1, pXcX-CMV-EmGFP-miR155/GPR37 and pXcX-CMV-EmGFP-249 
miR155/negative. AVV were then produced by homologous recombination of shuttle and 250 
the helper plasmid pBHG10 in HEK293 cells. The media was collected for subsequent rounds 251 
of AVV proliferation in HEK293 cells until cytopathic effects were achieved. AVV were 252 
purified using CsCl gradient protocols. Titers were established using an immunoreactivity 253 
spot assay as described previously (Duale et al., 2005). 254 
PSAP depletion 255 
To deplete PSAP from culture media (DMEM supplemented with 5% FBS), initially, 25 µl of 256 
Protein A Magnetic Beads (NEB) per 200 µl media were added and incubated for 1 hour at 257 
4°C. Magnetic field was applied for 30 seconds to pull beads to the side of the tube and the 258 
supernatant was transferred to a new tube. This step is required to remove non-specific 259 
binding proteins. Then, 5 μl of anti-PSAP antibody (500 μg/ml) were added to the 260 
supernatant and incubated for 1 hour at 4°C. Protein A Magnetic Beads were used again to 261 
pull down the antibody-bound PSAP. Western blot was used to verify the efficient removal 262 
of PSAP which could then be recovered from the beads (Fig. S4). 263 
264 
cAMP assays 265 
Two types of detection were used. 266 
Luminescence activity-based GloSensor assay (Promega). The GloSensor assay uses 267 
genetically encoded biosensor variants with cAMP binding domains fused to mutant forms 268 
of Photinus pyralis luciferase. The luminescence of the reporter increases directly 269 
proportionally to the amount of cAMP present. Astrocytes were seeded in 96-well plates 270 
and transduced with an AVV bearing the CMV-driven GLO22F. at multiplicity of infection 271 
(MOI) 10. Advice and assistance of Dr HJ Bailes HJis acknowledged. 24 hours after 272 
transduction, media was exchanged for 100 ul HEPES-buffered HBSS (pH7.6). Cells were 273 
then incubated with 0.731mMbeetle luciferin for 2 hours in the dark. After baseline reading, 274 
NKH477 and/or TX14(A) were added to the wells and incubated for 20 mins. Luminescence 275 
measurements were obtained using a Tecan microplate reader (Infinite M200 PRO).  276 
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FRET-based cAMP assay: Two to three days prior to recordings, astrocytes were plated onto 277 
coverslips in prosaposin-depleted media (PDM) and transduced with an AVV to express an 278 
Epac [Exchange protein directly activated by cAMP)-based FRET sensor (kindly provided by 279 
Jalink K, Amsterdam(Klarenbeek et al., 2015;Klarenbeek & Jalink, 2014)] specifically in 280 
astrocytes. PDM was exchanged daily. For recording, coverslips were placed into a chamber 281 
on a confocal microscope and continuously superfused with HEPES-buffered solution (HBS; 282 
in mM: NaCl 137, KCl 5.4, Na2HPO4 0.34, KH2PO4 0.44, CaCl2 1.67, MgSO4 0.8, NaHCO3 4.2, 283 
HEPES 10, Glucose 5.5; pH 7.4, 31.4°C). After taking baseline readings of astrocytes in the 284 
field of view, cells were exposed to 5 mins of NKH477 (0.5 µM), alone or in combination 285 
with TX14(A) (100 nM). Fluctuations in cAMP were monitored through CFP/YFP (465-286 
500nm/515-595nm bands) emission ratios upon 458 nm light excitation. Images were 287 
acquired every 4 seconds. All FRET ratios were normalized to baseline. 288 
289 
PRESTO-Tango β-arrestin-recruitment assay 290 
To measure receptor activation, the PRESTO-Tango β-arrestin-recruitment assay was 291 
performed as previously described, with modifications (Kroeze et al., 2015). HTLA cells, a 292 
HEK293 cell line stably expressing a tTA-dependent luciferase reporter and a β-arrestin2-TEV 293 
fusion gene, were used. The cells were maintained in DMEM media supplemented with 10% 294 
FBS, 100 U/ml penicillin and 100 μg/ml streptomycin, 2 μg/ml puromycin and 100 μg/ml 295 
hygromycin B. For transfection, HTLA cells were plated in 96-well white polystyrene plates 296 
(Greiner Bio-One) in DMEM media supplemented with 10% FBS, 100 U/ml penicillin and 100 297 
μg/ml streptomycin at a density of 4x10
5
 cells/ml. For measuring activation of GPR37 and298 
GPR37L1 by TX14(A) stimulation, PDM was used instead. After 16 hours, cells were 299 
transfected with the plasmid containing the GPR37 or GPR37L1 ORF (Addgene) using Trans-300 
IT 293 (Mirus) according to manufacturer’s protocol. On the next day, drugs were added in 301 
assay buffer (20 mM HEPES in HBSS, pH 7.4) and left to incubate for 24 hours. Solutions 302 
were aspirated, and 80 μl per well of Bright-Glo solution (Promega) diluted 20-fold in assay 303 
buffer was added to each well in the dark. Following 20 mins of incubation, luminescence 304 
measurements were obtained using a Tecan microplate reader (Infinite M200 PRO).  305 
306 
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Scratch Wound Assay 307 
A wound recovery assay was carried out to analyze the migration of astrocytes using the 308 
IncuCyte system (Essen BioScience). Primary astrocytes were seeded in ImageLock 96-well 309 
plates (4379, Essen BioScience) at a density of 4x10
4
 per well. After 24 hours, standardized 310 
and reproducible (700-800 μm wide) scratch ‘wounds’ were created in all wells using a 311 
dedicated device. Cultures were exposed to different testing conditions, e.g. stressors, and 312 
were maintained and imaged at hourly intervals up to 72 hours.  313 
Cell density was measured in the scratch area and compared to undisrupted adjacent 314 
monolayer. Relative wound density (%), a measure of wound recovery, was calculated using 315 
the formula: Relative wound density (%) = (density of wound region at certain time point – 316 
initial density of wound region)/(density of intact cell region at certain time point - initial 317 
density of wound) x 100. 318 
319 
DAPI staining 320 
Astrocytes were seeded in 96-well plate (1x10
4
 per well) and fixed in 4% paraformaldehyde 321 
for 5 mins, washed in PBS three times for 5 mins each time before and after incubating with 322 
1 μg/ ml DAPI for 10 mins. Round and whole nuclei in 9 fields of view per well were counted 323 
using ImageJ. 324 
325 
BrdU Incorporation Assay 326 
In order to detect cell division, astrocytes were seeded in a 96-well plate (4x10
3
 per well) in327 
media supplemented with 5% FBS or PDM and cultured for one day. BrdU was added to the 328 
wells at a final concentration of 10 µM. 24 hrs later, cells were fixed with 4% 329 
paraformaldehyde in PBS (pH 7.4) for 10 mins at room temperature and permeabilized with 330 
0.1~0.25% Triton X-100 in PBS. Cells were then incubated with 1 M HCl for 30 mins, followed 331 
by primary antibody incubation with mouse monoclonal anti-BrdU antibody (1:100) 332 
containing 2.5% goat serum at 4℃ overnight. Before imaging, cells were incubated with 333 
Alexa Fluor 488-conjugated goat anti-mouse secondary antibody for 30 mins at room 334 
temperature.  335 
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336 
Lactate dehydrogenase (LDH) release assay 337 
LDH release from damaged cells was assessed calorimetrically with LDH Cytotoxicity Assay 338 
Kit (Pierce) according to the manufacturer’s instructions. Activity is proportional to 339 
colorimetric reduction of tetrazolium salt measured at 490 nm. Cytotoxicity was normalized 340 
to maximal LDH activity as released from cells acutely exposed to Triton X-100, and 341 
calculated using the formula: % Cytotoxicity = (Compound-treated LDH activity – 342 
Spontaneous LDH activity)/(Maximum LDH activity – Spontaneous LDH activity) × 100. 343 
To determine the protective effect of prosaptide TX14(A) against oxidative stress on primary 344 
astrocytes, cells were seeded in triplicates in 96-well plates (4x10
4
 per well) in PDM and 345 
transduced with AVV-CMV-EmGFP-miR155/negative (labelled as miRNA-negative in the 346 
figures), or a mixture of AVV-CMV-EmGFP-miR155/GPR37L1 and AVV-CMV-EmGFP-347 
miR155/GPR37 (molar ratio 3:1, labeled as miRNA-GPR37L1/GPR37 in figures). 24 hours 348 
later, the media was replaced by fresh PDM and cells were treated with H2O2 (250 μM), 349 
staurosporine (200 nM) and rotenone (100 μM) for 5 hrs in the presence or absence of 350 
TX14(A). The media was then replaced by fresh PDM with or without TX14(A). Cells were 351 
incubated for a further 24 hours before carrying out the LDH reaction on 50 μl of media.  352 
For the protective effect of astrocytes on stressed neurons in the co-culture system, 353 
astrocytes or neurons were transduced with AVV at MOI 10. For astrocytes, cells were 354 
transduced at the time of plating on cell culture inserts. For neurons, cells were transduced 355 
on day 3 after preparation and then plated. 24 hrs later, media were replaced. Cells were 356 
cultured for 7 more days before they were treated with H2O2 (250 µM, 1 hr), rotenone (50 357 
µM, 2 hrs) or staurosporine (100 nM, 2 hrs). Stressors were then removed and neurons 358 
were incubated with or without astrocytes inserts. 24 hrs later, the LDH reaction was using 359 
50 μl of media. Cytoprotection was calculated using the formula: % Cytoprotection = % 360 
cytotoxicity in the control condition - %cytotoxicity in the experimental conditon. 361 
362 
Reagents 363 
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Cell culture and cell-based assays related: Beetle luciferin potassium salt (E1602, Promega); 364 
B27 (17504044, Life Technologies); Bovine serum albumin (BSA) fraction V (A3294, Sigma); 365 
BrdU (AB142567, Abcam); Bright-Glo™ reagent (E2610, Promega); Cytosine β-D-366 
arabinofuranoside  (C1768, Sigma); DNase I (D5025, Sigma); DAPI (D9542, Sigma); 367 
Dulbecco's Modified Eagle Medium (DMEM) (61965, Life Technologies); Fetal Bovine Serum 368 
(FBS, 10082147, Life Technologies); GlutaMax (35050038, Life Technologies ); L-Glutamine 369 
(2503008, Life Technologies); Hank’s Balanced Salt Solution (HBSS) (14175-129, Invitrogen); 370 
HEPES (H3375, Sigma); Horse serum (H1138, Sigma); Hygromycin B (H3274, Sigma); 371 
Kynurenic acid (K3375, Sigma); Neurobasal-A media (10888022, Life Technologies); 372 
Penicillin/Streptomycin (15140-122, Life Technologies); Poly-D-Lysine (A-003-E, Millipore); 373 
Protein A Magnetic Beads (NEB, S1425S); Puromycin (P8833, Sigma);Triton X-100 (T8787, 374 
Sigma); Trypsin (type III, bovine fraction) (T9935, Sigma). Ambion Power SYBR Green Cells to 375 
Ct kit (4402953) was used to verify GPR37L1 and GPR37 expression in cultured and acutely 376 
isolated astrocytes. 377 
Antibodies: Alexa Fluor 488-conjugated goat anti-rabbit secondary antibody (R37116, Life 378 
Technologies); Alexa Fluor 488-conjugated goat anti-mouse secondary antibody (R37120, 379 
Life technologies); GPR37 L1 antibody (AB151518, Abcam); GPR37 antibody (14820-1-AP, 380 
Proteintech); mouse monoclonal anti-BrdU antibody (GTX27781, GeneTex); pan-cadherin 381 
antibody (AB6529, Abcam); rabbit anti-PSAP antibody (AB68466, Abcam). 382 
Drugs: 6-BenZ-cAMP (B009-10, BIOLOG Life Science Institute); 8-pCPT-2’-O-Me-cAMP (C041-383 
05, BIOLOG Life Science Institute); H2O2 (H1009, Sigma); Pertussis toxin (3097, Tocris); NKH 384 
477 (SC-204130, Santa Cruz Biotechnology); Prosaptide TX14(A) (5151, Tocris); Rotenone 385 
(R8875, Sigma); Staurosporine (10042804, Fisher).  386 
All other chemicals were from Sigma. 387 
388 
Statistical Analysis 389 
All data analysis was performed with GraphPad Prism 7 (GraphPad Software Inc.). One-way 390 
ANOVA with one of the post-hoc analysis was used, unless otherwise stated. *p<0.05, 391 
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**p<0.01, ***p<0.001, ****p<0.0001. Grouped data are presented as mean ± SD, unless 392 
otherwise stated. 393 
Further details of statistical procedures can be found in the associated Excel file 394 
“Supplemental Statistics”. 395 
396 
397 
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RESULTS 398 
GPR37L1/GPR37 activation by prosaptide inhibits cAMP production in astrocytes but not 399 
in HEK293 cells  400 
Consistent with published information, GPR37L1 is strongly expressed by cultured rat 401 
astrocytes which also express GPR37 at a lower level. We have also confirmed that both 402 
receptors are present in acutely isolated cortical astrocytes from P12 rats, consistent with 403 
various published transcriptomes (Fig S2,3). Therefore, we always targeted both receptors 404 
simultaneously. A powerful double knock-down of GPR37L1 and GPR37 was achieved by 405 
modifying conventional micro-RNA based cassettes to incorporate 3 anti-target hairpins 406 
fused to the 3’-end of the Emerald green protein (Fig. 1A; (Liu et al., 2010)). These “triple-407 
hit” cassettes suppressed GPR37L1 and GPR37 protein expression below our detection limits 408 
while a negative control sequence had no impact (Fig 1B). The efficacy of the knock-down 409 
was additionally confirmed using Real Time PCR (Fig S5). To ensure maximal transduction of 410 
astrocytes we used adenoviral vectors (AVV) which are exceptionally effective tools for 411 
these cells (Fig S6). 412 
To assess intracellular cAMP changes, AVV were also used to express the Glosensor 413 
biosensor (Promega™). Baseline levels of cAMP were raised ~20-fold using a water soluble 414 
forskolin analogue, NKH477. On that background, TX14(A) concentration-dependently 415 
decreased cAMP with an IC50 of 17.8 nM (Fig. 1C). The maximal concentration of TX14(A) 416 
used (200 nM) inhibited NKH477-mediated cAMP production by approximately 40% (Fig. 417 
1C). The decrease of cAMP induced by TX14(A) was pertussis toxin (PTX) sensitive (Fig. 1D). 418 
Expression of the negative control miRNA vector had no effect while combined knock-down 419 
of the GPR37L1 and GPR37 receptors completely obliterated the TX14(A)-mediated 420 
decrease in cAMP levels (Fig. 1C). In addition, we employed an EPAC-based high affinity 421 
FRET sensor for cAMP (Klarenbeek et al., 2015) to visualize cAMP dynamics following 422 
TX14(A) application and found that TX14(A) (100 nM) significantly reduced the NKH477-423 
evoked rise in FRET ratio (Fig. 1 E,F).  424 
Several previous reports which failed to confirm the TX14(A) effect on GPR37L1 and GPR37 425 
used transiently transfected HEK293 cells. To verify that in HEK293 cells GPR37L1 and GPR37 426 
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signaling is different to that in astrocytes (Fig. 1 C-F), we used the PRESTO-Tango system 427 
(Kroeze et al., 2015). It provides GPCRs adapted for transient expression in a HEK293 line, 428 
modified to detect agonist-induced GPCR internalization. In that assay, GPR37 was 429 
constitutively active (compared to the baseline with ADRA1, Fig. S7) and both receptors 430 
were insensitive to prosaptide TX14(A) (Fig. 2), while the α-adrenoceptor 1a (ADRA1a) 431 
demonstrated an appropriate response (Fig. S7). The most likely explanation for this 432 
difference is that GPR37L1 and GPR37 require some additional proteins for their correct 433 
function which are lacking in HEK293 cells. Further analysis of this issue is outside of the 434 
scope of the current study. 435 
PSAP and TX14(A) acting via GPR37L1/GPR37 are essential for the motility of astrocytes 436 
Body fluids such as milk, blood and cerebrospinal fluid, contain PSAP (Kishimoto et al., 437 
1992). Most media used for culturing are supplemented with fetal bovine serum (FBS). 438 
Unsurprisingly, PSAP was present in FBS-supplemented media (Fig. S4). We studied the 439 
effect of PSAP depletion, using immunoadsorption (Fig. S4), on the motility of astrocytes in a 440 
wound scratch assay. Reproducible (700-800 µM wide) scratch wounds were created in 441 
astrocyte monolayers. In FBS-containing media, the wound essentially closed within 48 442 
hours (Fig. 3A; Suppl movie 1). This process was drastically slowed down by PSAP depletion. 443 
100 nM TX14(A) almost completely compensated for the loss of PSAP (Fig. 3A-C; Suppl 444 
movies 2 and 3). Importantly, knock-down of GPR37L1/GPR37 in astrocytes blocked the 445 
ability of TX14(A) to facilitate wound closure while the control vector was ineffective (Fig. 446 
3C, Suppl movies 4 and 5). Astrocytes divide in culture, albeit very slowly, but neither 447 
depletion of PSAP nor addition of TX14(A) affected the number of cells in cultures (Fig. 3D) 448 
nor the number of newly divided cells based on BrdU staining (Fig. 3E). Therefore, the 449 
effects of PSAP and TX14(A) in the scratch assay are due to their effect on the motility of 450 
astrocytes. 451 
Stimulation of adenylate cyclase with NKH477 (1 to 10 µM) greatly slowed down wound 452 
closure, as did the cAMP analogue 6-benz-cAMP (250 to 1000 µM), a selective PKA activator, 453 
in a concentration-dependent manner (Fig. 4A). The cAMP analogue 8-pCPT-2’-O-Me-cAMP 454 
(250 to 1000 µM) which specifically activates EPAC (cAMP-GEF) had no effect (Fig. 4A). 455 
Interestingly, non-selective stimulation of cAMP production by NKH477 as well as 456 
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stimulation of PKA by 6-BenZ-cAMP and of EPAC by 8-pCPT-2’-O-Me-cAMP reduced 457 
proliferative activity of astrocytes (Figs. 3D, 4B). Since all three cAMP raising drugs had a 458 
similar effect on cell numbers but different effects on wound closure dynamics, there 459 
appears to be no direct relationship between these two effects of cAMP. Taken together, 460 
the data indicate that the key mechanism of wound closure which is regulated via the 461 
GPR37L1/GPR37 axis is the lateral movement of astrocytes, rather than their division. 462 
PSAP and prosaptide protect astrocytes from oxidative stress damage via GPR37L1/GPR37 463 
Exposure of astrocytes to H2O2, rotenone or staurosporine drastically inhibited their ability 464 
to close the wound in PSAP-depleted media but TX14(A) rescued the stressed astrocytes’ 465 
wound closure capacity (Fig. 5A). This effect of TX14(A) was eliminated by the knock-down 466 
of GPR37L1/GPR37 in astrocytes, while the control knock-down vector was ineffective (Fig. 467 
5A).  468 
It has been previously reported that the death of cortical astrocytes triggered by H2O2 can 469 
be reduced by TX14(A) (Meyer et al., 2013). We adjusted concentrations and exposure time 470 
of H2O2, rotenone and staurosporine to evoke a comparable degree of cytotoxicity as 471 
assessed by LDH release assay (Fig. 5B). In PSAP-depleted media, neither GPR37L1/GPR37 472 
knock-down, nor the negative control vector, changed the cytotoxic impact of stressors. 473 
TX14(A) strongly reduced cytotoxicity which was particularly prominent in the case of 474 
staurosporine, and this was prevented by GPR37L1/GPR37 knock-down (Fig. 5B). 475 
Astrocytic GPR37L1/GPR37 signaling contributes to the protection of the cortical neurons 476 
from damage by oxidative stressors 477 
Neuronal cultures were subjected to the same oxidative stressors as above and conditions 478 
were adjusted to trigger a comparable degree of damage, based on LDH release. After 479 
removal of the stressors, astrocytes were introduced into the wells on elevated membranes, 480 
thereby preventing direct cell-cell contact (Fig. 6A). Astrocytes exerted a strong protective 481 
effect on the neurons which was directly proportional to the quantity of astrocytes (Fig. 6B; 482 
Fig. S8). 75k astrocytes per well provided a near-maximum neuroprotective effect and this 483 
astrocyte density was used for further experiments. 484 
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TX14(A) applied directly to damaged cultured neurons at 100 nM, provided a slight but 485 
significant protection against the stressors (Fig. 6C). This indicates that either neuronal 486 
GPR37L1/GPR37 receptors, or the few astrocytes remaining in the neuronal cultures, could 487 
be contributing to the neuroprotective actions of PSAP. 488 
Fig. 6D demonstrates that, for each of the 3 stressors, co-culturing with astrocytes reduced 489 
LDH release by ~35 - 45%. Importantly, the media used in these experiments was FBS-free 490 
and contained no added PSAP. However, when anti-PSAP antibodies were added, the 491 
cytoprotective effect of astrocytes was dramatically reduced (Fig. 6D). This strongly suggests 492 
that endogenous PSAP (or Sap C) in the co-culture system is important for the 493 
cytoprotective effect of astrocytes. We were able to immunodetect directly the increase in 494 
PSAP in co-culture media in response to H2O2 stress applied to neurons (Fig. S9), although 495 
the cellular source of this the stress-induced PSAP surge is currently unknown. Knock-down 496 
of GPR37L1/GPR37 selectively in astrocytes limited astrocyte-mediated neuroprotection to 497 
a degree comparable to PSAP depletion (Fig. 6D). Interestingly, application of the same 498 
knock-down AVV to neurons had no effect. These results are consistent with the idea that 499 
stress-induced PSAP release and astrocytic GPR37L1/GPR37 signaling are critical for PSAP 500 
action.  501 
502 
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Discussion 503 
The key message of this study is that the original coupling of PSAP and its prosaptide 504 
fragments to GPR37L1 and GPR37 suggested by (Meyer et al., 2013) was correct. This 505 
implies that we can expect small molecules based around the structure of TX14(A) be astro- 506 
and neuroprotective. 507 
Neuroprotection by PSAP 508 
The first cells, used to demonstrate a protective potential of PSAP were mouse 509 
neuroblastoma NS20Y and human neuroblastoma SK-N-MC cells (O'Brien et al., 1994). 510 
Interestingly, the neuroblastoma lines closely related to SK-N-MC express substantial levels 511 
of GPR37 (Harenza et al., 2017). Published transcriptomes of astrocytes (Zhang et al., 512 
2016;Zhang et al., 2014;Anderson et al., 2016;Chai et al., 2017) and our own data (Fig S2,3) 513 
unequivocally demonstrate that astrocytes of various parts of the central nervous system 514 
express high levels of GPR37L1 while the level of GPR37 is generally much lower. 515 
Cytoprotective and “trophic” effects of PSAP and its fragments were found in diverse 516 
models and species. Prosaptides improved the outcome of sciatic nerve damage in guinea 517 
pigs (Kotani et al., 1996a), alleviated the ischemia-induced memory deficits in gerbils (Kotani 518 
et al., 1996b), reduced neuropathy in diabetic rats (Calcutt et al., 1999), and the behavioral 519 
and anatomical detriments caused by brain wound insult in rats (Hozumi et al., 1999). A 520 
stabilized TX14(A)-like peptide, retro-inverso prosaptide D5, was neuroprotective in rats (Lu 521 
et al., 2000) and ameliorated hyperalgesia in a model of neuropathic pain (Yan et al., 2000). 522 
The neuroprotective effects of TX14(A) were confirmed by another group (Jolivalt et al., 523 
2006;Sun et al., 2002;Jolivalt et al., 2008). An 18-amino acid long prosaptide was also 524 
protective in a model of dopaminergic neuron damage (Sun et al., 2002;Gao et al., 2013). 525 
Therefore, there is solid evidence for the neuroprotective potential of this pathway. 526 
PSAP-GPR37L1/GPR37 pairing 527 
All these effects obviously called for the development of a neuroprotective therapy, but this 528 
opportunity could not be realized in the absence of cognate receptors. The study by (Meyer 529 
et al., 2013) strongly suggested that these are the orphan receptors GPR37L1 and GPR37. 530 
Some of the effects were demonstrated in HEK293 cells, but the most striking protective 531 
effect of TX14(A) was observed in cultured astrocytes. The findings of (Meyer et al., 2013) 532 
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were later criticized, the key concerns being the high concentration of TX14(A) used, the 533 
small magnitude of the Gi-mediated inhibitory effect on cAMP concentration and the failure 534 
to detect TX14(A) agonism in a β-arrestin-based DiscoverX assay (Southern et al., 535 
2013;Smith, 2015). Other recent studies reported high constitutive activity of GPR37L1 and 536 
GPR37 and lack of a TX14(A) effect in either HEK293 cells or yeast (Ngo et al., 2017;Giddens 537 
et al., 2017;Southern et al., 2013;Coleman et al., 2016).  538 
Our findings, however, are consistent with the conclusions drawn by (Meyer et al., 2013). 539 
The presence of PSAP in the media or addition of TX14(A) had a powerful effect on 540 
astrocytic motility and protected them against oxidative stressors. In all cases this action 541 
could be completely prevented by knocking down GPR37L1/GPR37 (Figs. 3A-C, 5). 542 
Moreover, when astrocytes were used to rescue neurons subjected to oxidative stress, 543 
removal of GPR37L1/GPR37 only from astrocytes was sufficient to significantly weaken their 544 
neuroprotective capacity and block the protective action of TX14(A) (Fig. 6D). TX14(A) at a 545 
fairly high concentration (100 nM) had a weak direct protective effect on stressed neurons 546 
which is unlikely to make a major contribution to the neuroprotection seen in the presence 547 
of astrocytes (Fig. 6C). At least, application of the knock-down strategy to neurons was 548 
without an obvious effect (Fig. 6D). 549 
Therefore, by several approaches, we demonstrate that the effects of PSAP and TX14(A) on 550 
astrocytes are invariably dependent on GPR37L1/GPR37. The partial protection provided to 551 
injured neurons by co-cultured astrocytes to some extent also depends on this signaling 552 
pathway. Given that only removal of GPR37L1/GPR37 from astrocytes, but not neurons 553 
interfered with neuroprotection in this paradigm, the likeliest scenario is that PSAP acts as 554 
an autocrine signal on the receptors located on the astrocytes to recruit additional, 555 
unidentified, neuroprotective molecules (Fig. 7).  556 
Previous studies in mice lacking either of the two receptors demonstrated various, albeit 557 
relatively mild, phenotypes but, to the best of our knowledge, the possibility of 558 
compensation by the remaining receptor in a single knockout scenario has never been 559 
explored. This could be the reason why the pro-seizure phenotype of double 560 
GPR37L1/GPR37 knockout mice is so severe (Giddens et al., 2017). Recent demonstration of 561 
a lethal neurological phenotype in humans with a point mutation in GPR37L1 (Giddens et 562 
al., 2017) suggests that GPR37L1 is potentially indispensable for the health of the human 563 
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brain. A drastic increase in neuronal loss after an ischemic stroke in GPR37L1 knockout mice 564 
(Jolly et al., 2017) further reinforces the importance of these receptors.  565 
Coupling 566 
The first study to indicate that a Gi-coupled receptor may mediate the action of PSAP found 567 
that pretreatment with PTX inhibited agonist-stimulated binding of [
35
S]-GTPγS (Hiraiwa et568 
al., 1997). Strikingly, it also demonstrated that Sap C interacts with a receptor of ~54 kDa, 569 
corresponding almost exactly to the molecular mass of GPR37L1(Giddens et al., 2017). In 570 
our study in astrocytes, TX14(A) inhibited cAMP production by approximately 40% from an 571 
elevated level set by the forskolin analogue (Glosensor assay). The effect of TX14(A) was PTX 572 
sensitive and the IC50 compares with that of numerous other GPCR agonists. Removal of 573 
GPR37L1 and GPR37 completely prevented the effect of TX14(A). These results confirm the 574 
original report (Meyer et al., 2013) that GPR37L1/GPR37 are Gi-coupled receptors. Coupling 575 
to other G-proteins needs to be investigated further. 576 
In the wound scratch assay, PSAP and TX14(A) were permissive to the spread of astrocytes 577 
into the barren area. This was due to an effect on lateral motility (Fig. 3D-E). Again, this 578 
effect was completely prevented by knock-down of the two receptors (Fig. 3C). 579 
Interestingly, stimulants of the cAMP pathway, the adenylyl cyclase activator NKH477, and 580 
two pathway-biased agonists, 6-BenZ-cAMP and 8-pCPT-2’-O-Me-cAMP, reduced the speed 581 
of division of cultured astrocytes (Fig 4B) but only 6-BenZ-cAMP which predominantly 582 
activates PKA (Bos, 2003) concentration-dependently suppressed spread of the astrocytes 583 
into the wounded area (Fig. 4A). Therefore, the motility of astrocytes is regulated by PKA, 584 
rather than EPAC-regulated proteins. TX14(A) did not interfere with the reduction in mitotic 585 
activity by either of the cAMP analogues (Fig. 4B). The mechanism by which PKA regulates 586 
astrocyte motility is currently unknown. 587 
Controversy related to PSAP-GPR37L1/GPR37 pairing 588 
Neither HEK293 cells nor yeast used in the recent conflicting studies (Ngo et al., 589 
2017;Giddens et al., 2017;Coleman et al., 2016) express GPR37L1 or GPR37 natively, nor 590 
were they ever demonstrated to be responsive to PSAP or prosaptides. These cells might 591 
not necessarily recapitulate the intracellular environment of astrocytes and neurons which 592 
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are the natural habitats of GPR37L1 and GPR37. Our experiments using PRESTO-Tango 593 
confirmed that neither GPR37L1 nor GPR37 respond to TX14A in HEK293 cells (Fig. 2). 594 
Serum-containing media can mask the effects of GPR37L1/GPR37 ligands because it 595 
contains considerable levels of PSAP. Most likely astrocytes, neurons or both can secrete 596 
some PSAP in vivo. This was visible in the “rescue” experiments where astrocytes reduced 597 
the damage caused to neurons by added stressors. In these experiments anti-PSAP 598 
antibodies reduced neuroprotection even though the media was nominally devoid of PSAP. 599 
In the presence of stressed neurons, PSAP was greatly upregulated and easily detected in 600 
the media by immunoblotting. Therefore, to fully reveal the agonist activity of TX14(A) it is 601 
important to ensure that the receptors are not persistently exposed to endogenous or 602 
media-derived PSAP. 603 
Taken together, our results demonstrate that prosaptide TX14(A) (and, by extension, PSAP) 604 
are the natural ligands of GPR37L1/GPR37 and confirm that in their native environment, the 605 
astrocyte, these receptors couple to the Gi cascade as originally reported (Meyer et al., 606 
2013). Their native signaling is however, lacking or suppressed in cell lines (such as 607 
transiently transfected HEK293 cells) used in β-arresting-based screening assays indicating 608 
that for correct coupling GPR37L1 and GPR37 may require as yet unknown intracellular 609 
partners present in astrocytes. This would not be a unique situation since some other 610 
receptors, such as CGRP receptor, are known to require co-expression of receptor-611 
associated proteins. Of note, astrocytes express very high levels of syntenin-1, which is 612 
important for trafficking of GPR37 (Dunham et al., 2009). It is conceivable that its role 613 
includes more than just trafficking. Given the powerful glio-protection and neuro-protection 614 
mediated by these receptors and since GPCRs are the most “druggable” class of proteins 615 
currently known, GPR37L1 (and GPR37, if they can be separated pharmacologically) become 616 
highly valuable targets for development of novel neuroprotective therapies. 617 
618 
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Figure legends 619 
Fig. 1. TX14 (A) acting on GPR37L1/GPR37 reduces cAMP levels in astrocytes. 620 
A: Layout of the adenoviral vectors for knock-down of GPR37L1 and GPR37. Each vector 621 
allows co-cistronic expression of three pre-miRNAs targeting different regions of the target 622 
gene. AVV: human adenoviral vectors serotype 5; CMV: human cytomegalovirus promoter; 623 
EmGFP: Emerald Green Fluorescent Protein; miR155: flanking pre-miRNA sequence derived 624 
from miR-155. 625 
B: Western blot confirms that AVV-CMV-EmGFP-miR155/GPR37L1 and AVV-CMV-EmGFP-626 
miR155/GPR37 (MOI 10) efficiently knock-down GPR37L1 and GPR37 in astrocytes. AVV-627 
CMV-EmGFP-miR155/negative is a control vector with hairpin sequence relevant to no 628 
known vertebrate gene. 629 
C: Concentration-response curves for inhibition of cAMP production by TX14(A) in 630 
astrocytes pre-treated with 1 µM NKH477. Cells were transduced with AVV-CMV-Glosensor 631 
and either AVV-CMV-EGFP (control), a mixture of AVV-CMV-EmGFP-miR155/GPR37L1 and 632 
AVV-CMV-EmGFP-miR155/GPR37 to knock-down GPR37L1/GPR37, or with AVV-CMV-633 
EmGFP-miR155/negative ( n= 4, triplicates). 634 
D: AVV-CMV-Glosensor transduced astrocytes were pretreated with PTX (20 hrs, 100 635 
ng/mL). 100 nM TX14(A)-induced cAMP reduction in astrocytes was PTX sensitive (n = 12, 636 
*** P <0.001 vs. indicated group, one-way ANOVA with Turkey’s post-hoc analysis). 637 
E: Astrocytes expressing an EPAC-based cAMP sensor were kept in PSAP-depleted media 638 
overnight and were stimulated with NKH477 (0.5 µM) in absence or presence of TX14(A) 639 
(100 nM). TX14(A) decreased the transient cAMP signal; average of 58 astrocytes from 4 640 
experiments.  641 
F: Pooled data from E shows significantly decreased FRET ratio peaks with TX14(A) (n=58= 642 
**** P < 0.0001, paired t-test). 643 
Fig. 2. 644 
GPR37L1 and GPR37 are non-responsive to prosaptide TX14-(A) in PRESTO-Tango assay in 645 
HEK293 cells.  646 
PRESTO-Tango uses clones of numerous human GPCR, C-terminally tagged with a special 647 
signaling element. These receptors need to be expressed in a specially designed clone of 648 
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HEK293 cells. Agonist binding triggers receptor internalization and eventually leads to 649 
expression of luciferase and luminescence. Two concentrations of plasmid DNA were used 650 
to express the tagged receptors. GPR37 exhibits strong constitutive activity, especially when 651 
using 0.1 μg/μl. Values obtained with 0.1 μg of GPR37 DNA could not be fitted with the 652 
regression algorithm of Prizm software, hence no line is shown (n=6). 653 
Fig. 3. PSAP/GPR37L1/GPR37–mediated signaling is essential for migration of astrocytes in 654 
the scratch assay and the effect of PSAP is mimicked by TX14(A). 655 
A: Astrocytes move into a wound in media containing 5% FBS and in PDM (prosaposin-656 
depleted media) supplemented with 100 nM TX14(A) but the movement is inhibited in 657 
absence of PSAP. Representative images at 0, 24 and 48 hours post scratch. See also 658 
supplementary movies 1-3.  659 
B: Dynamics of the relative wound density under conditions shown in A (n= 3, triplicates). 660 
C: Relative wound density 48 hrs post scratch for astrocytes incubated in FBS-containing 661 
media, PDM, PDM +TX14(A), PDM+TX14(A)+both knock-down vectors and PDM+TX14(A)+ 662 
knock-down control vector n = 6, triplicates, *** P <0.001 vs. indicated group, one-way 663 
ANOVA with Turkey’s post-hoc analysis).  664 
D: DAPI staining revealed no significant differences in the cell density between astrocytes 665 
cultured in media (+FBS), PDM and PDM supplemented with TX14(A) (100 nM) (n= 15). 666 
E: Addition of TX14 to PDM does not affect the numbers of new astrocytes based on BrdU 667 
staining (n = 7, triplicates).  668 
Fig. 4. cAMP in astrocytes affects wound closure in the scratch assay. 669 
A: A scratch wound was created in astrocyte monolayers cultured in FBS-containing media 670 
or PDM supplemented with 100 nM TX14(A). Drugs were added and dynamics of the wound 671 
closure was monitored for 72 hrs (n = 5, triplicates).  672 
B: DAPI staining of astrocytes shows that NKH477 (10 µM), 6-BenZ-cAMP (500 µM), and 8-673 
pCPT-2’-O-Me-cAMP (1000 µM) significantly decreased cell numbers as compared to 674 
control. (n= 4, triplicates).  675 
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In both cases, one-way ANOVA with Dunnett's post-hoc analysis. ** P <0.01, *** P <0.001 vs. 676 
control. 677 
Fig. 5. TX14(A) acts via GPR37L1 and GPR37 to protect primary astrocytes against toxicity 678 
induced by H2O2, staurosporine or rotenone. 679 
A: Pre-exposure to stressors (5 hours) drastically reduce relative wound density recorded at 680 
48 hrs in PDM. TX14(A) (100 nM) rescued astrocytes bringing wound density close to normal 681 
(compare to Fig 3). GPR37L1/GPR37 knock-down prevented the protective effect of TX14(A), 682 
while the control vector had no effect (n = 6, triplicates, *** P <0.001 vs. indicated group). 683 
B: LDH release was used as a measure of cytotoxicity, 24 hrs after exposure of astrocytes to 684 
oxidative stress. In PDM manipulation of GPR37L1/GPR37 had no effect. TX14(A) (100 nM) 685 
protected them from damage but only when they were expressing GPR37L1/GPR37, (n = 6, 686 
triplicates, ** P <0.01, *** P <0.001 vs. control group, e.g. PDM groups). 687 
One-way ANOVA with Bonferroni’s post-hoc analysis. 688 
689 
Fig. 6. Co-cultured astrocytes protect cortical neurons against oxidative toxicity partially 690 
through GPR37L1/GPR37 signaling in astrocytes. 691 
A: Experimental design:  a - stressed neurons (blue) in absence or presence of astrocytes 692 
(green) on a culture insert; b - depletion of PSAP from the media with anti-PSAP antibodies; 693 
c - GPR37L1 and GPR37 knock-down in astrocytes co-cultured with neurons; d - GPR37L1 694 
and GPR37 knock-down in neurons in the co-culture system. 695 
Neurons were treated with H2O2 (250 µM) for 1 hr, or staurosporine (100 nM) or rotenone 696 
(50 µM) for two hrs. Stressors were then removed and inserts with astrocytes were 697 
introduced. LDH assay was carried out 24 hr later. 698 
B: Astrocytes protect cortical neurons against H2O2-induced stress, the effect saturates at 699 
~75k astrocytes per co-culture (n= 5, triplicates,  *** P <0.001 vs. control (no astrocytes 700 
insert),**** P <0.0001 vs. groups with less than 50k astrocytes, one way ANOVA with 701 
Tukey’s post-hoc analysis). 702 
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C: TX14(A) has a weak protective effect on neurons against oxidative stress (n = 6, 703 
triplicates, *** P <0.001, **** P <0.0001  vs 50 nM TX14(A) group (effect of 50 nM is not 704 
significant, one way ANOVA with Bonferoni’s post-hoc analysis). 705 
D: PSAP depletion or GPR37L1/GPR37 knock-down selectively in astrocytes significantly 706 
attenuates the protective effect of astrocytes on neurons pre-exposed to oxidative stressors 707 
(n = 6, triplicates, *** P <0.001 vs. indicated group, one-way ANOVA with Turkey’s post-hoc 708 
analysis). 709 
Fig. 7. Working model of the neuroprotective role of astrocytic GPR37L1/GPR37 based on 710 
the evidence presented in this study.  711 
Damaged neurons release diffusible “SOS” factor(s) which trigger release of PSAP. PSAP acts 712 
on GPR37L1 on astrocytes and activates release of diffusible neuroprotective factor(s). 713 
714 
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SUPPLEMENTARY FIGURES 715 
S1. Alignment of prosaptide TX14 against PSAP of various species 716 
S2. Expression levels of several GPR37L1, GPR37 assessed by next generation sequencing 717 
S3. Expression levels of GPR37L1 and GPR37 in cultured and acutely isolated rat astrocytes 718 
assessed by Real Time PCR 719 
S4. Immunodetection of PSAP contained in fetal calf serum and cell culture media 720 
S5. GPR37L1 and GPR37 knockdown efficiency verified by Real Time PCR 721 
S6. Astrocytes and neurons transduced with AVV-miRNA-GPR37L1/37 722 
S7. Response of Adra 1a receptor to norepinephrine detected by Presto-TANGO system 723 
S8. Astrocytes protect cortical neurons against oxidative stress induced by rotenone and 724 
staurosporine in a “number”-dependent manner. 725 
S9. PSAP is produced by astrocytes and neurones. 726 
727 
728 
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SUPPLEMENTARY MOVIES 729 
730 
Supplementary Movie 1. 731 
Wound closure dynamics in full media 732 
733 
Supplementary Movie 2 734 
Wound closure dynamics in PSAP depleted media (PDM) 735 
736 
Supplementary Movie 3 737 
Wound closure dynamics in PSAP depleted media supplemented with TX14(A) 100 nM 738 
739 
Supplementary Movie 4 740 
Wound closure dynamics in PSAP depleted media supplemented with TX14(A) 100 nM in 741 
astrocytes where GPR37L1 and GPR37 were knocked down 742 
743 
Supplementary Movie 5 744 
Wound closure dynamics in PSAP depleted media supplemented with TX14(A) 100 nM in 745 
astrocytes treated with vectors expressing control (negative) knock-down cassette 746 
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